3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
102
Breast Neoplasms
10
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Triple Negative Breast Neoplasms
5
Castration-resistant Prostate Cancer
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
Prostate Cancer Metastatic
2
Prostate Adenocarcinoma
2
Ovarian Neoplasms
2
Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Metastatic Castration-Resistant Prostate Cancer
2
Metastatic Castration Resistant Prostate Cancer
2
Castration Resistant Metastatic Prostate Cancer
2
Carcinoma, Hepatocellular
2
Adenocarcinoma of the Prostate
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Thrombocytosis
1
Stomach Neoplasms
1
Solid Tumor
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Interventions
Nutrition Assessment
2
Blood Specimen Collection
2
spartalizumab
1
pembrolizumab
1
etelcalcetide hydrochloride
1
enzalutamide
1
bicalutamide
1
aldesleukin
1
Valsartan
1
Stents
1
Specimen Handling
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Lysine Acetyltransferase 5
1
Leuprolide
1
Interleukin-2
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Goserelin
1
Flutamide
1
Cisplatin
1
Adalimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Kidney Diseases
×
enzalutamide
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled